The Biotech Industry is driven by catalysts. It is crucial for investors to monitor recent events and analyze the impact they have had on share prices. The Biotech Industry has slumped as recent news has caused some dramatic swings, with the losses more than offsetting the gains. The iShares NASDAQ Biotechnology Index ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have dropped roughly 5.7 percent and 3.2 percent, respectively, in the past week.
Aastrom Biosciences Inc. (NASDAQ: ASTM) shares traded in the range of $0.29 to $0.31 Thursday before settling to close at $0.30, an increase of 1.04 percent. The stock appears to be facing some resistance at the $0.33, $0.40 and $0.44 levels. The company earlier this week announced the pricing of a public offering of 29 million shares of its common stocks at $0.30 per share.
More information on Aastrom Biosciences and access to the free equity report can be found at:
Inovio Pharmaceuticals Inc. (NYSEMKT: INO) shares traded in the range of $1.55 to $1.79 Thursday before settling to close at $1.59, an increase of 5.30 percent. The stock appears to be facing some resistance at the $1.67 and $1.82 levels with some support at $1.49. The company reported net loss for the second quarter of 2013 grew to $10.9 million from a loss of $4.1 million a year ago.
More information on Inovio Pharmaceuticals and access to the free equity report can be found at:
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) shares traded in the range of $3.52 to $3.82 Thursday before settling to close at $3.53, a decrease of 5.61 percent. The stock appears to be facing some resistance at the $4.25, $4.80 and $4.96 levels. The company reported net loss for the second quarter of 2013 grew to $30.3 million from a loss of $20.1 million a year ago.
More information on Merrimack Pharmaceuticals and access to the free equity report can be found at:
Vical Incorporated (NASDAQ: VICL) shares traded in the range of $1.43 to $1.50 Thursday before settling to close at $1.45, a decrease of 3.97 percent. The stock appears to be facing some resistance at the $2.95, $3.14 and $3.27 levels. The company fell sharply earlier this week after announcing a Phase 3 Trial of Allovectin failed to meet is efficacy endpoints.
More information on Vical and access to the free equity report can be found at:
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Wall Street Fundamentals